Pages that link to "Q27888393"
Jump to navigation
Jump to search
The following pages link to abiraterone acetate (Q27888393):
Displaying 50 items.
- Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer (Q24646000) (← links)
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study (Q28275476) (← links)
- Zytiga (Q29006769) (← links)
- Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. (Q33770362) (← links)
- Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate (Q33770374) (← links)
- Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer (Q34578443) (← links)
- Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer. (Q34619574) (← links)
- The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature. (Q34629038) (← links)
- Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. (Q34798892) (← links)
- TMPRSS2-ERG Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated With Abiraterone Acetate (Q35256427) (← links)
- Effects of Abiraterone Acetate on Androgen Signaling in Castrate-Resistant Prostate Cancer in Bone (Q35808422) (← links)
- Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men (Q35996237) (← links)
- Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer (Q36117284) (← links)
- Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer (Q36504117) (← links)
- Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic Response (Q36854826) (← links)
- Abiraterone acetate for castration resistant prostate cancer (Q37708308) (← links)
- Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer (Q37829693) (← links)
- Abiraterone acetate in castration-resistant prostate cancer (Q37962151) (← links)
- Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor. (Q37963173) (← links)
- Abiraterone acetate: redefining hormone treatment for advanced prostate cancer (Q37971267) (← links)
- Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer (Q37980116) (← links)
- Abiraterone acetate: a novel drug for castration-resistant prostate carcinoma (Q38047794) (← links)
- Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer? (Q39372450) (← links)
- Abiraterone acetate, an inhibitor of adrenal androgen synthesis in "hormone refractory prostate cancer" (Q41850941) (← links)
- Abiraterone acetate for prostate cancer: a new era of hormonal therapies. (Q41997785) (← links)
- Abiraterone acetate is well tolerated without concomitant use of corticosteroids (Q42921826) (← links)
- Efficacy of abiraterone acetate in post-docetaxel castration-resistant prostate cancer (Q42964655) (← links)
- A phase I, open-label, single-dose, mass balance study of 14C-labeled abiraterone acetate in healthy male subjects (Q45240509) (← links)
- (Q57134814) (← links)
- Abiraterone acetate (Zytiga) for metastatic castration-resistant prostate cancer (Q57136210) (← links)
- Abiraterone Acetate: A Guide to Its Use in Metastatic Castration-Resistant Prostate Cancer (Q60486503) (← links)
- Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy (Q61915102) (← links)
- An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy (Q61918521) (← links)
- Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer (Q61956016) (← links)
- Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (Q61957427) (← links)
- A Study to Assess the Effect of Abiraterone Acetate in Male Participants With Mild or Moderate Hepatic Impairment Compared to Matched Control Participants With Normal Hepatic Function (Q61969203) (← links)
- Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients (Q61969681) (← links)
- Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer (Q61969720) (← links)
- Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC) (Q61969744) (← links)
- Effects of Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Radiation on Prostate Cancer (Q62025470) (← links)
- A Randomized Phase III Study - Conventional ADT w/ or w/Out Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT (Q62030698) (← links)
- A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer (Q62034171) (← links)
- Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (Q63315712) (← links)
- A Study to Assess the Effect of Timing of Food Intake on the Pharmacokinetics of Abiraterone Following Single-Dose Administration of Abiraterone Acetate Tablets in Healthy Caucasian and Japanese Men (Q63315785) (← links)
- Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer (Q63317999) (← links)
- A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency (Q63319280) (← links)
- A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer (Q63321432) (← links)
- A Study to Assess the Relative Bioavailability of Two Abiraterone Acetate Suspension Formulations Compared to the Abiraterone Acetate Tablet Formulation in Healthy Adult Volunteers (Q63334694) (← links)
- IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen (Q63338649) (← links)
- Study to Evaluate CCS1477 in Advanced Tumours (Q63397743) (← links)